IMPORTANT MEDICAL DISCLAIMER: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Clinical judgment is always paramount in patient care.

---

Celiac

Overview

• Definition: Celiac disease (CD) is a chronic, immune-mediated enteropathy of the small intestine that occurs in genetically predisposed individuals following ingestion of gluten-containing grains (wheat, barley, rye). It is characterized by small intestinal villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes, leading to nutrient malabsorption.
• Epidemiology:
  • Prevalence: Affects approximately 1% of the global population, though it is often underdiagnosed.
  • Demographics: More common in individuals of European descent. There is a slight female predominance (ratio ~2:1).
  • Risk groups: Higher prevalence in first-degree relatives of CD patients (5-15%), individuals with other autoimmune diseases (e.g., Type 1 Diabetes Mellitus, autoimmune thyroiditis), and genetic disorders (e.g., Down Syndrome, Turner Syndrome, Williams Syndrome).
  • Asymptomatic cases: A significant proportion of individuals with CD remain undiagnosed due to absent or atypical symptoms.
• Classification:
  • Classical Celiac Disease: Presents with prominent signs and symptoms of malabsorption (e.g., diarrhea, weight loss, abdominal distension, steatorrhea).
  • Atypical/Non-classical Celiac Disease: Characterized by milder or absent gastrointestinal symptoms, with predominant extra-intestinal manifestations (e.g., iron deficiency anemia, osteoporosis, fatigue, neurological symptoms, dermatitis herpetiformis). This is the most common presentation in adults.
  • Silent Celiac Disease: Individuals have positive serology and small bowel villous atrophy but are asymptomatic. Diagnosed incidentally (e.g., during screening of at-risk groups).
  • Potential Celiac Disease: Individuals have positive celiac-specific antibodies (e.g., tTG-IgA) but normal small bowel mucosa. These individuals are at risk of developing overt CD over time.
  • Refractory Celiac Disease (RCD): Persistent or recurrent symptoms and villous atrophy despite strict adherence to a gluten-free diet for at least 12 months, in the absence of other causes. Classified into Type 1 (normal intraepithelial lymphocytes phenotype) and Type 2 (abnormal clonal intraepithelial lymphocytes with high risk of progression to enteropathy-associated T-cell lymphoma, EATL).
  • Non-Celiac Gluten Sensitivity (NCGS): A distinct condition characterized by intestinal and/or extra-intestinal symptoms that improve on a gluten-free diet, but without the autoimmune markers or small bowel damage characteristic of celiac disease. Not considered a form of celiac disease.

Pathophysiology

• Mechanism:
  • Genetic predisposition (HLA-DQ2 and/or HLA-DQ8 alleles, present in >95% of CD patients, but also in 30% of general population).
  • Ingestion of gluten: Gluten, a protein complex found in wheat, barley, and rye, is partially digested in the human gut. The indigestible gliadin peptides cross the intestinal epithelial barrier.
  • Deamidation by tissue transglutaminase (tTG): Within the lamina propria, the enzyme tTG deamidates gliadin peptides, increasing their negative charge and enhancing their binding affinity to HLA-DQ2/DQ8 molecules on antigen-presenting cells (APCs).
  • Immune activation: The deamidated gliadin peptides are presented by APCs to CD4+ T-cells, triggering an adaptive immune response. This leads to the production of pro-inflammatory cytokines, activation of B-cells to produce autoantibodies (e.g., anti-tTG, anti-endomysial, anti-DGP), and a cytotoxic T-cell response against enterocytes.
  • Intestinal damage: The chronic inflammatory response causes characteristic damage to the small intestinal mucosa, including villous atrophy (flattening of the villi), crypt hyperplasia (elongation of the crypts), and increased intraepithelial lymphocytes (IELs). This damage impairs nutrient absorption, leading to the clinical manifestations of malabsorption.
• Risk Factors:
  • Genetic: Presence of HLA-DQ2 and/or HLA-DQ8 haplotypes.
  • Family history of CD (first-degree relatives have a 10-15% risk).
  • Co-existing autoimmune diseases: Type 1 Diabetes Mellitus (up to 10% prevalence), autoimmune thyroiditis (5-10%), primary biliary cholangitis, microscopic colitis, Sjogren's syndrome.
  • Genetic syndromes: Down Syndrome (5-10%), Turner Syndrome, Williams Syndrome.
  • IgA deficiency (higher prevalence of CD, necessitates IgG-based testing).
  • Certain infections (e.g., rotavirus, adenovirus) and alterations in gut microbiota may play a role as triggers, though evidence is not definitive.
• Protective Factors:
  • No definitively proven protective factors that prevent the development of celiac disease in genetically susceptible individuals.
  • Controversial and largely unproven: Duration of breastfeeding, timing and amount of gluten introduction in infancy (current evidence suggests no benefit in delaying or avoiding gluten).

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Chronic diarrhea (often steatorrhea)
  • Weight loss or failure to thrive (in children)
  • Abdominal pain, bloating, distension
  • Fatigue
  • Iron deficiency anemia (often refractory to oral iron supplementation)
• Early Signs:
  • Non-specific fatigue
  • Mild abdominal discomfort
  • Unexplained iron deficiency anemia
  • Oral aphthous ulcers
  • Dental enamel defects
• Advanced Signs:
  • Severe malnutrition (muscle wasting, cachexia)
  • Osteoporosis/osteomalacia (due to vitamin D and calcium malabsorption)
  • Peripheral edema (due to hypoalbuminemia)
  • Neurological symptoms (e.g., ataxia, peripheral neuropathy, epilepsy with cerebral calcifications, "brain fog")
  • Reproductive issues (e.g., infertility, recurrent miscarriage, delayed puberty)
  • Dermatitis herpetiformis (intensely pruritic, blistering skin rash, pathognomonic for CD)
• Atypical Presentations:
  • Most common presentation in adults.
  • Iron deficiency anemia (most frequent isolated manifestation)
  • Osteoporosis
  • Elevated liver transaminases (often unexplained)
  • Chronic fatigue syndrome
  • Peripheral neuropathy
  • Recurrent aphthous stomatitis
  • Dental enamel hypoplasia

Physical Examination

• Inspection:
  • Pallor (due to anemia)
  • Signs of malnutrition (muscle wasting, cachexia, brittle hair/nails)
  • Dermatitis herpetiformis (symmetrical erythematous papules and vesicles, often on elbows, knees, buttocks, scalp; scratched lesions may present as excoriations)
  • Peripheral edema (due to hypoalbuminemia)
  • Abdominal distension
  • Cheilosis, glossitis (vitamin deficiencies)
  • Dental enamel defects (pitting, grooving, discoloration)
• Palpation:
  • Mild abdominal tenderness
  • Bowel loops may be palpable in very thin individuals with distension.
• Special Tests:
  • No specific physical maneuvers for CD diagnosis. Focus is on assessing nutritional status and signs of complications.

Diagnostic Approach

History Taking

• Key Questions:
  • Detailed dietary history, including gluten consumption (essential to be on a gluten-containing diet for accurate testing).
  • Family history of celiac disease or other autoimmune conditions.
  • Gastrointestinal symptoms: diarrhea (frequency, consistency, steatorrhea), abdominal pain, bloating, nausea, vomiting, constipation.
  • Extra-intestinal symptoms: fatigue, weight changes, bone pain, joint pain, skin rashes (especially pruritic blistering), neurological symptoms, menstrual irregularities, dental problems.
  • History of other autoimmune conditions (Type 1 DM, thyroid disease).
  • History of unexplained anemia, osteoporosis, or elevated liver enzymes.
  • Response to gluten exclusion, if attempted (though this should not precede formal diagnosis).
• Red Flags:
  • Chronic diarrhea, especially with weight loss.
  • Unexplained iron deficiency anemia.
  • Persistent elevated liver transaminases.
  • Unexplained osteoporosis in a younger individual.
  • First-degree relative with known celiac disease and new onset symptoms.
  • Dermatitis herpetiformis.

Laboratory Tests

Note: All serological testing should be performed while the patient is consuming a gluten-containing diet (at least 2 slices of bread daily for 6-8 weeks) for accurate results. A gluten-free diet before testing can lead to false negatives. - First-Line: - Total Serum IgA: To rule out IgA deficiency, which can cause false-negative results for IgA-based tests. If IgA deficient, IgG-based tests are required. - Tissue Transglutaminase IgA (tTG-IgA): Highly sensitive (95-98%) and specific (95-97%) for CD. It is the preferred initial screening test for individuals >2 years of age. A value >10 times the upper limit of normal (ULN) in symptomatic individuals, combined with a positive Endomysial Antibody (EMA) and positive HLA-DQ2/DQ8, may allow for diagnosis without biopsy in children per ESPGHAN guidelines. - Deamidated Gliadin Peptide IgA (DGP-IgA): Used in conjunction with tTG-IgA, particularly useful in children <2 years where tTG-IgA sensitivity may be lower, and in IgA deficient individuals (as IgG-DGP). - Endomysial Antibody IgA (EMA-IgA): Highly specific (approaching 100%) but less sensitive and more labor-intensive than tTG-IgA. Often used as a confirmatory serologic test, especially when tTG-IgA is equivocal. - Confirmatory: - Small Bowel Biopsy: Gold standard for diagnosis in adults. Performed via Esophagogastroduodenoscopy (EGD) with at least 4-6 biopsies taken from the second part of the duodenum and duodenal bulb. - Histopathological Findings (Marsh Classification): - Marsh 0: Normal mucosa. - Marsh 1: Increased intraepithelial lymphocytes (>25 IELs per 100 enterocytes). - Marsh 2: Increased IELs + crypt hyperplasia. - Marsh 3: Increased IELs + crypt hyperplasia + villous atrophy (subdivided into 3a: partial, 3b: subtotal, 3c: total). Marsh 3 is diagnostic for CD. - HLA-DQ2/DQ8 Genetic Testing: - Not diagnostic for CD (many healthy individuals carry these alleles). - Highly effective as a negative predictor: A negative result (absence of both HLA-DQ2 and HLA-DQ8) essentially rules out celiac disease (>99% negative predictive value). Useful in ambiguous cases, potential celiac, or when ruling out CD in at-risk family members. - Monitoring: - Repeat tTG-IgA: To assess adherence to GFD and mucosal healing. Typically checked 6-12 months after GFD initiation, then annually until normalization, and periodically thereafter. - Complete Blood Count (CBC): To monitor for anemia. - Iron studies (ferritin, iron, TIBC): To assess iron stores. - Vitamin levels: 25-hydroxyvitamin D, B12, folate, calcium (especially at baseline and after GFD initiation). - Liver function tests (LFTs): To monitor for elevated enzymes. - Bone Mineral Density (BMD) via DEXA scan: Baseline at diagnosis, and repeat 1-2 years after GFD initiation or as clinically indicated to monitor for osteoporosis.

Imaging

• Recommended:
  • DEXA Scan: Recommended at diagnosis for adults to assess for osteopenia or osteoporosis due to malabsorption.
• Advanced:
  • CT/MR Enterography: Not for routine diagnosis. May be used in cases of refractory celiac disease to evaluate for complications such as ulcerative jejunitis, small bowel adenocarcinoma, or enteropathy-associated T-cell lymphoma (EATL), or to rule out other causes of persistent symptoms.
  • Capsule Endoscopy: May be considered for evaluation of the small bowel in refractory cases or if there is suspicion of small bowel malignancy not seen on standard EGD.

Management

Acute Management

• Immediate:
  • For acutely symptomatic patients, initiation of a strict, lifelong gluten-free diet (GFD) is the cornerstone.
  • If severe dehydration or electrolyte imbalances are present due to malabsorption, initiate intravenous fluid and electrolyte replacement.
  • Correct severe nutritional deficiencies (e.g., severe anemia requiring transfusion, if indicated).
• Stabilization:
  • Nutritional assessment and consultation with a registered dietitian specializing in CD is crucial to guide GFD adherence and address existing deficiencies.
  • Supplementation of vitamins and minerals:
    • Iron: Oral iron supplementation (e.g., ferrous sulfate 325 mg PO once or twice daily) for iron deficiency anemia.
    • Folate: 1 mg PO daily.
    • Vitamin B12: If deficient, oral (1000-2000 mcg daily) or intramuscular (1000 mcg monthly initially) depending on severity.
    • Vitamin D: 1000-2000 IU PO daily, with dose adjustment based on serum levels.
    • Calcium: 1000-1200 mg PO daily.
• Emergency:
  • Severe, acute malabsorption leading to life-threatening electrolyte disturbances or profound malnutrition requiring hospitalization for aggressive nutritional support (e.g., parenteral nutrition in extreme cases) is rare but can occur.
  • Management of an emergent complication (e.g., intestinal perforation, hemorrhage from ulcerative jejunitis) would follow general surgical/critical care principles.

Chronic Management

• Pharmacological:
  • Strict Gluten-Free Diet (GFD): The sole proven effective treatment. This involves lifelong avoidance of all foods containing wheat, barley, rye, and their derivatives. Oats can be tolerated by most CD patients if certified gluten-free (i.e., not cross-contaminated).
  • Corticosteroids: Used for severe symptoms, severe enteropathy, or in the initial management of refractory celiac disease.
    • Oral prednisone: Typical dosage 0.5-1 mg/kg/day, tapered over several weeks to months as symptoms improve and mucosal healing begins.
  • Immunosuppressants: For refractory celiac disease, especially Type 1 RCD or as part of RCD Type 2 management.
    • Azathioprine: 2-2.5 mg/kg/day.
    • Budesonide: A locally acting steroid, 9 mg/day.
    • Biologics: Anti-TNF agents (e.g., infliximab) or other novel agents (e.g., vedolizumab, ustekinumab) have been explored for refractory cases, but evidence is limited and off-label.
  • Chemotherapy: For RCD Type 2 that progresses to EATL (enteropathy-associated T-cell lymphoma).
• Non-pharmacological:
  • Dietary Education: Essential. Patients must understand label reading, cross-contamination risks, and sources of hidden gluten. Regular follow-up with a dietitian is crucial.
  • Support Groups: Can provide valuable resources and emotional support.
  • Psychological Support: Addressing anxiety or depression related to dietary restrictions or chronic illness.
• Monitoring:
  • Regular clinical follow-up: Annually with a gastroenterologist or primary care physician.
  • Serology: Repeat tTG-IgA levels every 6-12 months until normalization, then annually. Sustained elevation suggests ongoing gluten exposure.
  • Nutritional assessment: Regular monitoring of CBC, iron studies, vitamin D, B12, folate, and calcium levels.
  • Bone density: Repeat DEXA scan 1-2 years after diagnosis to confirm improvement or address ongoing osteopenia/osteoporosis.
  • Repeat endoscopy with biopsy: Generally not routinely recommended if symptoms resolve and serology normalizes. Indicated only if symptoms persist despite GFD, serology remains elevated, or new complications are suspected.

Treatment Algorithms

• First-Line:
  1. Diagnosis Confirmation: Serology (tTG-IgA, EMA-IgA, DGP-IgA, total IgA) while on gluten, followed by small bowel biopsy. HLA-DQ2/DQ8 testing for exclusion or equivocal cases.
  2. Strict Lifelong Gluten-Free Diet (GFD): Immediately initiate upon diagnosis.
  3. Nutritional Support: Dietitian consultation, vitamin/mineral supplementation as needed (iron, vitamin D, calcium, B12, folate).
• Second-Line:
  1. Persistent Symptoms Despite GFD: Re-evaluate adherence to GFD (including occult gluten exposure), rule out other causes of malabsorption (e.g., microscopic colitis, SIBO, exocrine pancreatic insufficiency, lactose intolerance).
  2. Short course of corticosteroids: For severe symptoms or acute exacerbations in confirmed RCD, e.g., prednisone 0.5-1 mg/kg/day, tapered.
• Refractory Cases:
  1. Confirm Diagnosis and Strict GFD Adherence: Re-biopsy to confirm persistent villous atrophy. Rigorously re-assess GFD adherence, including hidden gluten sources and cross-contamination.
  2. Exclude Mimics: Rule out other conditions causing villous atrophy (e.g., common variable immunodeficiency, tropical sprue, lymphoma, AIDS enteropathy, SIBO, medications like olmesartan).
  3. Classify Refractory Celiac Disease (RCD):
     • RCD Type 1: Normal intraepithelial lymphocyte phenotype. Managed with high-dose corticosteroids, possibly immunosuppressants (e.g., azathioprine, budesonide).
     • RCD Type 2: Abnormal clonal intraepithelial lymphocytes (detected by flow cytometry on biopsy). High risk of EATL. Management is complex and often involves a multidisciplinary team:
       • Immunosuppression: High-dose corticosteroids, azathioprine, cyclosporine, cladribine.
       • Novel therapies: Infliximab, vedolizumab, ustekinumab (experimental/off-label).
       • Close monitoring for lymphoma: Regular imaging, repeat biopsies.

Complications

• Common:
  • Nutritional deficiencies: Iron deficiency anemia (most common), vitamin D, B12, folate, calcium, zinc, fat-soluble vitamins (A, E, K).
  • Osteoporosis/Osteopenia: Due to chronic malabsorption of calcium and vitamin D.
  • Lactose Intolerance: Secondary to intestinal damage; often resolves with mucosal healing on GFD.
  • Functional Hyposplenism: Reduced splenic function leading to increased risk of encapsulated bacterial infections.
  • Dental enamel defects.
  • Infertility and adverse pregnancy outcomes (if untreated).
• Serious:
  • Refractory Celiac Disease (RCD): Persistent symptoms and villous atrophy despite strict GFD.
  • Enteropathy-Associated T-Cell Lymphoma (EATL): Rare, highly aggressive non-Hodgkin lymphoma, strongly associated with RCD Type 2. Presents with abdominal pain, obstruction, hemorrhage, weight loss.
  • Small Bowel Adenocarcinoma: Rare but increased risk, typically in patients with long-standing, uncontrolled CD.
  • Ulcerative Jejunitis: Non-specific inflammation of the jejunum with ulceration, can lead to strictures, perforations, and bleeding. Can be a precursor to EATL.
• Long-term:
  • Increased risk of other autoimmune diseases (e.g., Type 1 Diabetes, autoimmune thyroiditis, psoriasis).
  • Increased risk of microscopic colitis.
  • Increased risk of gastrointestinal malignancies (though overall absolute risk is small with GFD).

Prognosis

• Factors:
  • Adherence to GFD: The most critical factor. Strict, lifelong adherence leads to mucosal healing and symptom resolution.
  • Age at diagnosis: Younger age at diagnosis and GFD initiation generally associated with better prognosis and less risk of long-term complications.
  • Severity of initial disease: More severe villous atrophy or presence of complications at diagnosis may influence recovery time.
  • Development of complications: RCD, EATL, or other malignancies significantly worsen prognosis.
• Survival:
  • With strict adherence to a GFD, the mortality rate for most celiac patients is comparable to the general population.
  • Increased mortality risk is primarily associated with refractory celiac disease (especially RCD Type 2), development of EATL, or other associated malignancies.
• Quality of Life:
  • Significantly improves with adherence to a GFD, leading to resolution of symptoms and improved nutritional status.
  • Challenges include the social and practical difficulties of maintaining a strict GFD, which can impact psychological well-being. Education and support are key to good QoL.

Prevention

• Primary:
  • No proven primary prevention strategy. While HLA-DQ2/DQ8 carriage is necessary, it is not sufficient for CD development.
  • Early gluten introduction (before 6 months or after 12 months) or specific patterns of infant feeding (e.g., breastfeeding duration) have not been shown to prevent CD in genetically susceptible infants, based on current evidence.
• Secondary:
  • Screening of at-risk individuals:
    • First-degree relatives of patients with CD (serology recommended).
    • Individuals with Type 1 Diabetes Mellitus (annual serology for the first few years, then periodically).
    • Patients with other autoimmune diseases (e.g., autoimmune thyroiditis, Sjogren's syndrome, microscopic colitis) with suggestive symptoms.
    • Individuals with Down Syndrome, Turner Syndrome, Williams Syndrome.
    • Patients with unexplained iron deficiency anemia, chronic diarrhea, osteoporosis, or elevated LFTs.
• Tertiary:
  • Strict, lifelong GFD: This is the primary tertiary prevention strategy, preventing ongoing mucosal damage, resolving symptoms, reversing nutritional deficiencies, and reducing the risk of long-term complications like malignancies.
  • Regular follow-up: To monitor adherence, mucosal healing, and screen for potential complications.

Special Populations

• Pediatric:
  • Presentation: Often presents as failure to thrive, short stature, delayed puberty, abdominal pain, diarrhea, irritability.
  • Diagnosis: The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (2012, updated 2020) allow for diagnosis without biopsy in symptomatic children with:
    1. tTG-IgA level >10 times the upper limit of normal (ULN).
    2. A positive EMA-IgA test (on a separate blood sample).
    3. Positive HLA-DQ2/DQ8. - If these criteria are not met, or if symptoms are atypical, biopsy remains mandatory.
  • Management: Strict GFD, parental education, careful monitoring of growth and development.
• Geriatric:
  • Presentation: Often atypical, presenting as isolated iron deficiency anemia, osteoporosis, neurological symptoms, or non-specific fatigue. GI symptoms may be mild or absent. Diagnosis may be delayed.
  • Diagnosis: Serology and biopsy remain the gold standard. Lower tTG-IgA levels may be observed.
  • Management: GFD, with particular attention to bone health and nutrient deficiencies. Polypharmacy and comorbidities need careful consideration.
• Pregnancy:
  • Risks: Untreated CD can increase risks of miscarriage, intrauterine growth restriction, low birth weight, and preterm birth.
  • Management: Women with diagnosed CD should maintain a strict GFD before and throughout pregnancy. Close monitoring of iron, folate, and B12 levels is essential.
• Comorbidities:
  • Type 1 Diabetes Mellitus (T1DM): Screen all T1DM patients for CD due to high co-occurrence (up to 10%). CD can affect glycemic control.
  • Autoimmune Thyroiditis: Screen if symptomatic or with other CD risk factors.
  • Dermatitis Herpetiformis (DH): Almost all patients with DH have CD (even if asymptomatic GI involvement). Diagnosis of DH via skin biopsy (showing granular IgA deposits) should prompt investigation for CD.
  • IgA Deficiency: Individuals with IgA deficiency may have false-negative IgA-based celiac serology. In these cases, IgG-based tests (IgG-tTG, IgG-DGP) should be used, followed by biopsy if positive.

Clinical Pearls

• Diagnostic:
  • "Don't go gluten-free before the test!": Always ensure the patient is consuming gluten regularly before performing serology or endoscopy, otherwise, results can be falsely negative. If a patient has already started GFD, consider a gluten challenge (e.g., 2 slices of bread daily for 6-8 weeks) before retesting, although this can be difficult for patients.
  • High tTG-IgA is highly predictive: A tTG-IgA level >10x ULN, especially with strong clinical suspicion, significantly increases the likelihood of CD.
  • Biopsy is still the gold standard in adults: Even with positive serology, biopsy confirms intestinal damage and rules out other causes. Ensure adequate biopsy samples (at least 4 from the distal duodenum, and 2 from the duodenal bulb).
• Treatment:
  • GFD is the only treatment: Emphasize that strict, lifelong adherence is non-negotiable for symptom resolution and prevention of complications.
  • Cross-contamination is a major challenge: Educate patients on hidden gluten sources, shared kitchen utensils, toasters, deep fryers, and restaurant dining.
  • Symptom resolution is not immediate: Mucosal healing and symptom improvement can take weeks to months after starting GFD, and full recovery can take longer.
• Pitfalls:
  • Misdiagnosing IBS: Celiac disease symptoms can mimic irritable bowel syndrome (IBS). Always screen for CD in patients with IBS-like symptoms before labeling them as IBS.
  • Inadequate follow-up: Patients need ongoing support and monitoring for adherence, nutritional status, and development of complications.
  • Ignoring extra-intestinal symptoms: CD is not just a GI disease. Anemia, osteoporosis, fatigue, and neurological issues are common presentations and should trigger CD evaluation.

Recent Updates

• Guidelines:
  • ESPGHAN 2020 Guidelines: Reaffirmed the non-biopsy diagnosis pathway for symptomatic children with very high tTG-IgA levels.
  • American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) Guidelines: Continue to emphasize serology followed by biopsy for adults.
• Evidence:
  • Growing understanding of the role of the gut microbiome in CD pathogenesis, with ongoing research into potential therapeutic targets (e.g., probiotics, prebiotics, fecal microbiota transplantation).
  • Development of potential non-dietary therapies (e.g., gluten-degrading enzymes, tight junction modulators, immunomodulators), though none are currently approved or widely recommended for clinical use. These aim to reduce the burden of GFD.
• Controversies:
  • Need for repeat biopsy post-GFD: Current guidelines generally do not recommend routine repeat biopsy to confirm mucosal healing in asymptomatic patients with normalizing serology. However, it may be considered if symptoms persist, serology remains elevated, or in patients with RCD.
  • Management of Non-Celiac Gluten Sensitivity (NCGS): Distinction from CD remains critical. Diagnosis is by exclusion and response to a GFD followed by a gluten challenge, usually under medical supervision. Management involves GFD, but the strictness and duration are less defined than for CD.

Key References

• Guidelines:
  • American College of Gastroenterology (ACG) Clinical Guidelines: Diagnosis and Management of Celiac Disease (2013, 2021 updates pending).
  • European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Guidelines for the Diagnosis of Coeliac Disease (2012, updated 2020).
  • American Gastroenterological Association (AGA) Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease (2016).
• Studies:
  • Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012 Sep 13;367(15):1419-26. (Classic review on epidemiology and pathophysiology)
  • Lebwohl B, et al. Predictors of Celiac Disease in Patients with Positive Serology. Clin Gastroenterol Hepatol. 2017 May;15(5):715-722.e1.
  • Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):136-60. (Original non-biopsy pathway guidelines).
  • Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology and Nutrition Guidelines for the Diagnosis of Coeliac Disease – An Update. J Pediatr Gastroenterol Nutr. 2020 Jan;70(1):1-16. (Updated pediatric guidelines).
• Reviews:
  • Ludvigsson JF, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013 Jan;62(1):43-52.
  • Kelly CP, et al. Advances in Celiac Disease. Annu Rev Med. 2015;66:35-51.
  • Rubio-Tapia A, Murray JA. Celiac Disease. Annu Rev Med. 2021 Jan 27;72:147-157.